Gregoire Sylvie

Director Gregoire Sylvie buys 21,600 shares at $8.46 for $182,736.00; cluster of 4 insider buys in 14 days at unprofitable biotech.

Gregoire Sylvie, Director at unprofitable biotech CervoMed Inc. (net income: $-7.7M), completed 2 separate purchases on 2025-11-17 totaling 21,600 shares for $182,736.00 at a blended average price of $8.46. This follows 4 prior buys by the same insider at CRVO within the past 5 days (2025-11-12 through 2025-11-14), and coincides with a broader cluster in which 3 other insiders also bought within the past 14 days. The transaction occurred while the stock traded 39.7% below its 52-week high, though 30-day momentum is positive at +14.8%. The post-transaction holding of 12,500 shares indicates accumulation by this director despite the company's ongoing unprofitability ($-7.7M net income in the latest quarter) against the backdrop of strong revenue growth of +36.3% year-over-year. The cluster pattern and sustained buying by the same insider across consecutive days warrant attention to whether insiders perceive current valuation as attractive or whether external developments are driving coordinated accumulation.

Director Gregoire Sylvie purchased 7,847 shares at blended average $7.53 across 3 transactions; 3 other insiders also bought within 14 days.

Gregoire Sylvie, a Director at CervoMed Inc., executed 3 separate purchases totaling 7,847 shares for $59,101.11 between November 13–14, 2025, at prices ranging from $7.51 to $7.57. This filing reflects a cluster pattern: 3 other insiders also purchased shares within the past 14 days, suggesting coordinated confidence. However, the company's fundamentals present a mixed picture—while annual revenue growth reached +36.3%, the company posted a net loss of $-7.7M on quarterly revenue of $322.6K and remains unprofitable on a full-year basis. The stock currently trades at $8.21, up 16.0% over 30 days but down 42.6% from its 52-week high of $14.29. The insider's post-transaction holdings total 1,693 shares, indicating a position built through recent purchases rather than a long-established stake. The cluster buy pattern merits observation, though the underlying financial distress and recent share price volatility underscore fundamental execution risks.

Director Gregoire Sylvie buys 5,553 shares of CRVO at $7.35; stock down 49.3% from 52-week high amid cluster buy pattern.

Director Gregoire Sylvie purchased 5,553 shares at $7.35 on 2025-11-12, adding to an existing substantial position of 1.46M shares. The purchase occurs against a backdrop of significant price deterioration: the stock is down 49.3% from its 52-week high of $14.29 and has declined 11.8% over the past 30 days and 28.4% over 90 days. CervoMed posted negative full-year net income of $-7.7M on quarterly revenue of $322.6K, indicating the company is unprofitable despite 36.3% annual revenue growth. The transaction is part of a cluster buy pattern with 2 other insiders also purchasing within the past 14 days, suggesting coordinated insider accumulation at depressed levels. However, the director's cross-ticker track record shows only 1 prior buy across all open-market activity, limiting confidence in the signal strength of this single insider's purchasing pattern.